These findings offer a solid basis for designing clinical trials of therapies aimed at modifying the development of these neurodegenerative diseases1
Researchers at the Clínic-IDIBAPS led a study published in the Alzheimer’s & Dementia journal on the relationship between the integrity of the locus1
The centre becomes the first in Spain to use blood biomarker p-tau217, which offers a more accurate and less invasive diagnosis and marks a paradigm1
With the expansion of the Day Hospital for Neurodegenerative Diseases at the Clínic Barcelona Hospital, it will be possible to receive over 15,000 vi1
Frontotemporal dementia (FTD) and Alzheimer's disease are two different forms of dementia, which can often be confused due to sharing some of the sym1
Keeping the brain active is one of the main ways to prevent neurodegenerative diseases. There are many methods to stimulate the brain that involve bo1
Biological sex, that is, being born male or female, can influence different aspects of early-onset Alzheimer's disease (symptoms seen before the age1
A study by the hospital Clínic Barcelona-IDIBAPS, published in the journal Neurology, confirms the usefulness of a blood-based biomarker to diagnose1
There is no cure for Alzheimer's as yet, but patients' quality of life can be improved through cognitive intervention such as memory journalling.
The study, published in the journal Molecular Metabolism, has involved the participation of IDIBAPS researchers.
